Table 2.
Comparison interstitial lung disease (ILD) patients positive to anti-tRNA, with ILD progression, against subjects who evolved to improve ILD.
| Variable | Patients with ILD Progression n = 3 |
Patients without ILD Progression n = 36 |
p-Value |
|---|---|---|---|
| Age at baseline assessment | 52 (49–83) | 51 (45.5–56) | 0.42 |
| Female gender | 2 (66.6%) | 34 (94.45%) | 1.0 |
| Pulmonary symptoms before baseline evaluation | 12 (12–24) | 10.5 (3.5–20) | 0.33 |
| Anti-tRNA autoantibody | |||
| Jo1+ | 0 | 10 (27.77%) | |
| PL7+ | 1 (33.33%) | 7 (19.44%) | |
| PL12+ | 2 (66.66%) | 9 (25%) | |
| Ej+ | 0 | 10 (27.77%) | 0.27 |
| HRCT pattern | |||
| OP | 2 (66.66%) | 18 (50%) | |
| NSIP | 1 (33.33%) | 16 (44.44%) | |
| UIP | 0 | 2 (5.55%) | 1.0 |
| Lung disease extent in HRCT * | 63 (56–70) | 56 (40–62) | 0.34 |
| Ground glass extent in HRCT * | 53.2 (50.4–56) | 51.2 (34.4–57) | 0.86 |
| Fibrosis extent in HRCT * | 9.8 (5.6–14) | 4.96 (3.72–8.5) | 0.26 |
| Baseline % of predicted value of FVC (median, (IQR)) | 66 (36–77) | 49 (41.5–74) | 0.87 |
| Baseline % of predicted value of the DLCO | 55 (15–66) | 44.5 (33.5–67) | 0.95 |
| CK level at baseline | 42 (22–50) | 105.5 (72.5–516.5) | 0.01 |
| Arthritis | 2 | 1 | 1.0 |
| Fever | 1 | 2 | 1.0 |
| Modified Borg scale at rest | 4 (2.5–5) | 3 (2–3) | 0.21 |
| Modified Borg scale during activity | 6.5 (5–5.5) | 5 (4–6) | 0.17 |
* According to the Goh score [16].